Market Place
Sourcing Support
Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs
03 Feb 2023 //
BIOPHARMADIVE
Novartis and the (pCPA) conclude negotiations for Luxturna
20 Sep 2022 //
NEWSWIRE
In vivo gene editing grabs the spotlight after Intellia triumph
29 Sep 2021 //
FIERCEBIOTECH
Luxturna inventor launches new gene therapy biotech with $19M
23 Sep 2021 //
FIERCEBIOTECH
Horama refuels with a Series B expansion and a new name
20 Jul 2021 //
ENDPTS
First patient undergoes Luxturna gene therapy on NHS
18 Feb 2020 //
PHARMATIMES
Manufacturing: the next breakthrough in gene therapy
19 Dec 2019 //
STATNEWS
Aldevron, NTC Team Up for Gene Therapy Manufacturing
24 Oct 2019 //
CONTRACT PHARMA
ProQR eye-disease data lend confidence that pivotal trial will succeed
11 Oct 2019 //
BIOPHARMADIVE
Roche and Spark Continue to See Delays for Pending Deal
07 Sep 2019 //
BIOSPACE
Novartis, Spark gene therapies win a boost with soup-to-nuts Cigna coverage
07 Sep 2019 //
FIERCEPHARMA
UK cost watchdog recommends Novartis` blindness therapy Luxturna
05 Sep 2019 //
REUTERS
Poll Shows Americans Tolerate High Costs of One-Time Gene Therapies
28 Jun 2019 //
BIOSPACE
The top 10 most-expensive meds in the U.S.—and they`re not the usual suspects
13 Jun 2019 //
FIERCE PHARMA
Roche’s Acquisition of Spark Hits Another Regulatory Snag in the U.S. and U.K.
11 Jun 2019 //
BIOSPACE
Will Roche buy Spark on time—or ever—after third delay?
15 May 2019 //
FIERCE PHARMA
Two Gene Therapy Approvals Headline CBER’s FY 2018 Report
18 Apr 2019 //
RAPS
Johnson & Johnson dips a toe into gene therapy
31 Jan 2019 //
EVALUATE PHARMA
JPM19: Spark looks at scale, manufacturing as gene therapy matures
11 Jan 2019 //
BIOPHARMA DIVE
What do Martin Shkreli, Gilead and Takeda have in common?
06 Dec 2018 //
ENDPTS
Novartis gets European approval for sight therapy Luxturna
24 Nov 2018 //
REUTERS
Novartis gets European approval for sight therapy Luxturna
23 Nov 2018 //
REUTERS
Apitope CEO Keith Martin steps down; Clearside Biomedical taps Spark exec as CMO
27 Oct 2018 //
ENDPTS
CHMP puts 13 therapies forward for EU approval
24 Sep 2018 //
PHARMA TIMES
Gene therapy for rare inherited vision loss recommended for approval
22 Sep 2018 //
EMA
New therapy for rare disorder causing vision loss Recommended for approval
21 Sep 2018 //
EMA
CHMP Backs 13 New Medicines, Maintains Negative Opinion of Sarepta’s Exondys
21 Sep 2018 //
RAPS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.